Clinical Trial

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-18.
Trial Details
NCT Number NCT07370506
Lead Sponsor Tanta University
Conditions Breast Cancer, Doxorubicin Induced Cardiomyopathy
Enrollment 36 participants
Start Date 2026-02
Primary Completion 2027-01 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-29